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orgTbjectives: Positron emission tomographic maximal standardized uptake value has
een shown to predict survival after resection of non–small cell lung cancer. The
elative prognostic benefit of maximal standardized uptake value with respect to
ther clinical/pathologic variables has not been defined.
ethods: We reviewed patients who had positron emission tomographic imaging
nd an R0 resection for non–small cell lung cancer between January 1, 2000, and
ecember 31, 2004, without induction or adjuvant therapy. The associations be-
ween overall survival, histology, pathologic TNM stage, pathologic tumor diame-
er, and standardized uptake value were tested.
esults: Four hundred eighty-seven patients met the study criteria. Median follow-up
as 25.8 months. By using the median values for tumor size (2.5 cm) and
tandardized uptake value (5.3), standardized uptake value was an independent
redictor of survival (P  .03), adjusting for tumor size (P  .02) and histology (P
.01). The optimal standardized uptake value for stratification was identified as
.4, and this value was identified as an independent predictor of survival (P  .03)
fter adjusting for clinical TNM stage. Standardized uptake value was not an
ndependent predictor of survival (P  .09), adjusting for pathologic TNM stage
stage IA vs IB vs stage II–IV, P  .01).
onclusions: Standardized uptake value does not add to the prognostic significance
f pathologic TNM stage. Standardized uptake value was an independent prognostic
actor from clinical TNM stage.
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1
G
TShe standardized uptake value (SUV) for fluorine-18
fluorodeoxyglucose (18F-FDG) as measured by us-
ing positron emission tomography (PET) has been
hown to correlate with several measures of tumor behavior,
uch as lesion doubling time1 and Ki-67 staining,2 suggest-
ng that SUV might be a predictor of patient prognosis.
reviously, to determine whether 18F-FDG uptake in a
alignancy correlated with prognosis, we performed a ret-
ospective review of patients with histologically proved
on–small cell lung cancer (NSCLC) or carcinoid cancer
pathologic T1-4N0-2M0) who had undergone R0 resec-
ions after PET imaging and without either neoadjuvant or
djuvant therapy.3 We found that stratification of patients by
he median SUVMAX (which was 9) predicted survival; the
-year survival for patients with an SUVMAX of greater than
was 68%, and that for patients with an SUVMAX of less
han 9 was 96% (P  .01, log–rank test). However, an
nsufficient number of patients was available to allow an
nalysis of the relationship of SUVMAX to pathologic TMN
taging. Other reports have attempted to determine whether
UVMAX is an independent predictor from pathologic TNM
pTNM) staging of survival, but none have contained suf-
cient patients to allow a definitive answer.4-15 Results in
he published studies have been mixed, and possible reasons
or the conflicting results have been recently extensively
nalyzed in a review by Pillot and coauthors.16 To analyze
hether PET SUV was a predictor of survival independent
f pTNM staging, we reviewed our experience with a much
arger cohort of patients treated since our original report.
aterials and Methods
e performed a retrospective review of patients who had PET
maging and an R0 resection for NSCLC without induction or
djuvant therapy at Memorial Sloan-Kettering Cancer Center dur-
ng the period from January 1, 2000, through December 31, 2004.
he primary goal of this study was to determine whether SUVMAX
f the primary site of disease was an independent predictor of
urvival from clinical and pTNM staging.
This review was performed after approval had been obtained
rom the Memorial Sloan-Kettering Cancer Center Institutional
eview Board and in accord with an assurance filed with and
pproved by the Department of Health and Human Services.
Patient data were obtained from a prospectively maintained
atabase in the Memorial Sloan-Kettering Cancer Center Thoracic
Abbreviations and Acronyms
CT  computed tomography
18F-FDG  fluorine-18 fluorodeoxyglucose
NSCLC  non–small cell lung cancer
pTNM  pathologic TNM
SUV  standardized uptake value
SUVMAX maximal standardized uptake valueervice, in which patient staging information is entered on a s
420 The Journal of Thoracic and Cardiovascular Surgery ● Juneekly basis under attending surgeon supervision, and survival
ata were updated at regular intervals by research study assistants.
he primary end point was overall survival, which was calculated
rom the date of surgical intervention to the date of death or last
ontact with the patient.
Histologic characterization of the tumors was obtained from the
perative pathologic report. Patients undergoing resections of what
ere believed by the treating physicians to be synchronous or
etachronous (defined for the purpose of this study as within 5
ears of prior lung cancer) primary NSCLCs were not included.
umors were grouped into 3 categories: adenocarcinoma, squa-
ous cell carcinoma, and “other.” Patients who had no nodes
ampled at the time of resection were treated as having pathologic
0 disease. Adenosquamous carcinomas were included in the
other” category. If recorded, SUVMAX of the primary tumors was
btained from the radiology report, and if not recorded, it was
alculated by a Nuclear Medicine physician (TA) from PET im-
ges. For statistical analyses, clinical and pTNM stages were
ompressed to 3 groups: stage IA, stage IB, and stage II to IV.
Associations between overall survival and tumor histology,
linical TNM stage, pTNM stage, and pathologic maximal tumor
iameter were tested by using the log–rank test, and the associa-
ions between survival and SUVMAX of the primary site of disease
ere evaluated with Cox regression. In determining the interrela-
ion between SUV and variables that can be determined preoper-
tively, we used pathologically measured tumor size determined
rom pathology reports as a surrogate for imaging-based estimates
f tumor size and pathologic histology as a surrogate for histology
etermined from a fine- or core-needle biopsy. Estimation of the
ptimal values for stratification was performed by using the max-
mal 2 method. Multivariate modeling to identify independent
rognostic factors was performed by using Cox regression. Poor,
ntermediate, and good risk groups were identified by merging
ubgroups with similar subgroups through backward elimination
ollowing the Cox model. Thirty-three patients in the current
ohort had been included in the previously reported analysis3;
nalyses were performed with these patients excluded, and the
esults did not differ significantly from those found in the material
resented below (data not shown).
esults
our hundred eighty-seven patients met the study criteria.
atient demographics are recorded in Tables 1A, 1B, and
C. There was a predominance of male subjects (67%) and
f adenocarcinoma (69%). The majority of patients (87.5%)
nderwent anatomic resections. Pathologic stage was IA in
49 patients, IB in 132 patients, and IIA through IV in 106
atients. With a median follow-up of 25.8 months, 17 (3%)
atients have been lost to follow-up.
By using univariate analysis, tumor size (Figure 1) and
UV were determined to be significant predictors of survival
P  .02 and .03, respectively). Survival after resection strat-
fied by histology (Figure 2) demonstrated significant differ-
nces between adenocarcinoma and squamous carcinoma (P
05), adenocarcinoma and other histologies (P  .01), and
quamous carcinoma and other histologies (P  .05).
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SUVMAX, Maximal standardized uptake value.
T
Not available 8
T
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G
TSThe median SUV for adenocarcinoma was significantly
ifferent from that for the squamous carcinomas (P  .01)
nd that for the other histologies (P  .01). The median
UV values for squamous carcinoma and for other histol-
gies were not different (P  .69, Figure E1).
We first performed an analysis of significant prognostic
ariables using the median values for SUV and for patho-
ogic tumor size to avoid inadvertent bias. In an analysis
sing the median values for pathologically measured tumor
ize (2.5 cm) and tumor SUVMAX (5.3), SUVMAX was an
ndependent predictor of survival (P  .03) after adjusting
or tumor size (P  .02) and histology (P  .01). After
emonstrating that the median value for SUV was a signif-
cant independent predictor of survival, the optimal cut-off
oint for stratification was calculated as a tumor size of 3.3
m (P  .03) and an SUV of 4.3 (P  .01, Figure 3). This
ptimal value for SUV was an independent predictor of
urvival (P .03) after adjusting for clinical TNM stage (as
tage IA vs IB vs II-IV, P  .01). There was an interaction
etween SUV and clinical TNM stage in that SUV acted
ost strongly in the stratification of clinical TNM stage IB
Figure E2). Survival stratified by a combination of the
ptimal values for SUV and size demonstrated that patients
ith a size of greater than 2.5 cm and an SUV of greater
han 4.3 had a significantly worse survival when compared
ith all other patients (Figure 4).
The SUV in patients with pTNM stage IA disease was
ignificantly lower than that in patients with stage IB dis-
ABLE 1C. Pathologic TNM stage
Postresection stage
T
T1 283
T2 173
T3 13
T4 18
N
N0 395
N1 55
N2 27
N3 0
None sampled 10
M
M0 479
M1 8
Pathologic TNM
IA 249
IB 131
IIA 21
IIB 35
IIIA 27
IIIB 16
IV 8ABLE 1A. Patient demographics
ex
Male subjects 230
Female subjects 257
ge (y), median (range) 69 (27–87)
xtent of resection
Bilobectomy 18
Lobectomy 347
Pneumonectomy 19
Segmentectomy 41
Wedge 62
istology
Adenocarcinoma 337
Squamous 104
Other 46
athologic tumor size (mm), median (range) 25 (4–140)
UVMAX primary tumor 5.3 (0.6–36.3)
ollow-up (mo), median (range) 25.8 (1–66)
tatus at last follow-up
Alive with disease 38
Dead of disease 69
Dead of other causes 20
No evidence of disease 343
Lost to follow-up 17ABLE 1B. Clinical TNM stage
Clinical stage
T
T1 326
T2 153
T3 5
T4 3
N
N0 404
N1 54
N2 26
N3 2
M
M0 476
M1 4
Clinical TNM
IA 284
IB 105
IIA 20
IIB 34
IIIA 26
IIIB 6
IV 4ase (P  .01) and patients with stage II to IV disease (P 
and Cardiovascular Surgery ● Volume 133, Number 6 1421
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G
TS01). The SUV distribution between stage IB disease and
tage II to IV disease did not differ (P  .39, Figure E3).
urvival after resection stratified by pTNM stage (Figure
4) demonstrated significant differences between pTNM
tages IA, IB, and II to IV (P  .01). Neither the median
alue for SUV nor the calculated optimal SUV were inde-
endent predictors of survival (P  .09 for both) after
djusting for pTNM stage (stages IA vs IB vs II-IV, P 
01; Figures E5–E7).
Given that SUV was an independent prognostic variable
rom clinical TNM stage, we attempted to determine whether
here was a combination of prognostic variables available
reoperatively, including SUV, that could approximate the
rognostic information provided by the postoperative variables
f pTNM staging and pathologic histology.
Combining histology and pTNM stage, we identified the
ollowing 3 statistically significant postoperative prognostic
ategories (Figure 5): good—adenocarcinoma, pTNM stage
A; poor—large cell/sarcomatoid, pTNM stages II to IV;
ntermediate, all other patients.
Combining SUVMAX, pathologic tumor size, and histol-
gy, we identified the following statistically significant
reoperative prognostic categories (Figure 6): good—
denocarcinoma, SUV of less than 4.4 and size of less than
.5 cm; poor—large cell/sarcomatoid histology, SUV of
reater than 4.4 and size of greater than 2.5; intermediate—
ll others.
After complete pathologic staging, 394 (81%) of 487
atients remained in the same prognostic group that they
igure 1. Survival after resection stratified by optimal value for
aximal tumor diameter.ad been assigned to on the basis of clinical staging. The d
422 The Journal of Thoracic and Cardiovascular Surgery ● Jun9% (93/487) of patients who change prognostic groups
fter resection do so primarily by moving from a good to an
ntermediate prognosis (Table 2). The 3-year survival for
atients in the preoperative and postoperative good category
as 86% and 87%, respectively; 72% and 67%, respec-
ively, for the intermediate group; and 45% and 45%, re-
pectively, for the poor group.
iscussion
o determine whether PET SUV was a clinically relevant
rognostic parameter, we examined a uniform population of
atients who all had NSCLC of the lung resected with
urative intent after PET imaging at one institution and who
id not receive either induction or adjuvant therapy. Even
hough the number of patients available for analysis was
ore than twice the number (225) of surgically treated
atients in the prior largest series,17 to provide the highest
uality statistical analyses, we compared SUV as a prog-
ostic variable against 3 prognostic groupings of TNM
tages. After patients had been stratified into groups as
aving pTNM stage IA disease (small node-negative tu-
ors), stage IB disease (large node-negative tumors), and
tage II to IV disease (82/105 or 78% of whom had lymph
ode involvement), further stratification by means of PET
UV did not further define prognosis.
However, further stratification by means of PET SUV after
linical TNM staging significantly improved the prognosis.
his suggests that there might be a role for PET SUV in
igure 2. Survival after resection stratified by histology (P < .01
or adenocarcinoma [Adeno] vs other, P  .05 for adenocarci-
oma vs squamous, P  .05 for squamous vs other).efining patient prognosis preoperatively to help in determin-
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G
TSng which patients should be considered for induction therapy
r for definitive chemoradiotherapy rather than surgical inter-
ention. When we stratified patients on the basis of tumor
aximum diameter and histology (both of which are variables
hat can be approximated by preoperative imaging and needle
igure 3. Survival after resection stratified by optimal value for
aximal standardized uptake value of the primary tumor.
igure 4. Survival stratified by a combination of the optimal
alues for standardized uptake value (SUV) and tumor size, dem-
nstrating that patients with a tumor size of greater than 2.5 cm
nd an SUV of greater than 4.3 had significantly worse survival
hen compared with all other patients (P < .01). d
The Journal of Thoracicspiration, respectively), the addition of PET SUV further
mproved the definition of prognosis. It is worth noting that
ecause we used pathologic tumor size as a surrogate for
adiographically determined size and final pathology as a sur-
ogate for histology determined from a fine-needle aspiration
iopsy, it is likely that when radiographic size and histology by
ne-needle aspiration are compared with PET that the relative
rognostic benefit of determining SUV will improve. Radio-
igure 5. Survival stratified by a combination of histology and
athologic TNM stage.
igure 6. Survival stratified by a combination of histology, stan-
ardized uptake value, and tumor size.
and Cardiovascular Surgery ● Volume 133, Number 6 1423
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G
TSraphic estimates of the size of tumors can vary depending on
hether the adjacent lung is inflated at the time of sectioning.
t is possible that image-based estimates of tumor size might
ary, and therefore the utility of combining image-based tumor
ize with SUV to define prognosis should be tested formally.
In a model of how a preoperative stratification might
ork, we construct good-, intermediate-, and poor-prognosis
roups based on the postoperative prognostic variables of
TNM stage and pathologic histology. Statistical analysis
uggested that combinations of potentially available preop-
rative variables (SUV, tumor size, and histology) allowed
onstruction of good-, intermediate-, and poor-prognosis
roups that closely correlated with the postoperative cate-
ories in that only 19% of patients moved from one to
nother group preoperatively to postoperatively. This com-
ares very favorably with the current relationship between
linical and pathologic staging, in which approximately
0% of patients will shift stage. For example, Roberts and
olleagues18 found that T status as determined by means of
omputed tomographic (CT) imaging was concordant with
athologic T stage in only 56% of patients, with CT over-
taging 20% and understaging 24%. Similarly, Cerfolio and
oauthors17 found that after PET/CT and CT imaging, 52%
f patients clinically staged as N2 positive were actually N2
egative, and 14% of patients clinically staged as N2 neg-
tive were actually pathologically N2 positive.
Validation of the utility of PET SUV as a prognostic
ariable and the relative benefit of SUV in comparison with
maging measurements and tumor characteristics, such as
ene expression, has been undertaken in an attempt to better
uide patient therapy at the time of diagnosis rather than
fter resection.
eferences
1. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaugh Al, Coleman RE,
Wolfe WG. Lung tumor growth correlates with glucose metabolism
measured by fluorine-18 fluorodeoxyglucose positron emission tomog-
raphy. Ann Thorac Surg. 1995;60:1348-52.
2. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E,
ABLE 2. Preoperative versus postoperative risk group
tratification
reoperative (rows) vs postoperative (columns) I II III
190 72 0
I 12 177 6
II 0 3 27et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglu-
424 The Journal of Thoracic and Cardiovascular Surgery ● Juncose uptake by positron emission tomography. Clin Cancer Res.
2000;6:3837-44.
3. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S,
et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomog-
raphy maximal standardized uptake value predicts survival after lung
cancer resection. J Clin Oncol. 2004;22:3255-60.
4. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance
of fluorodeoxyglucose positron emission tomography imaging for patients
with nonsmall cell lung carcinoma. Cancer. 1998;83:918-24.
5. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum
standardized uptake values on positron emission tomography of a
non-small cell lung cancer predict stage, recurrence, and survival.
J Thorac Cardiovasc Surg. 2005;130:151-9.
6. Dhital K, Saunders CAB, Seed PT, O’Doherty MJ, Dussek J. 18F]Flu-
orodeoxyglucose positron emission tomography and its prognostic
value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-8.
7. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al.
18F-FDG uptake as a biologic prognostic factor for recurrence in
patients with surgically resection non-small cell lung cancer. J Nucl
Med. 2002;43:39-45.
8. Jeong H-J, Min J-J, Park JM, Chung J-K, Kim BT, Jeong JM, et al.
Determination of the prognostic value of [18F]fluorodeoxyglucose
uptake by using positron emission tomography in patients with non-
small cell lung cancer. Nucl Med Commun. 2002;23:865-70.
9. Kieninger AN, Welsh R, Bendick PJ, Zelenock G, Chmielewski GW.
Positron-emission tomography as a prognostic tool for early-stage lung
cancer. Am J Surg. 2006;191:433-6.
0. Port JL, Andrade RS, Levin MA, Korst RJ, Lee PC, Becker DE, et al.
Positron emission tomographic scanning in the diagnosis and staging
of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc
Surg. 2005;130:1611-5.
1. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K,
et al. [18F]fluorodeoxyglucose uptake by positron emission tomogra-
phy predicts outcome of non-small-cell lung cancer. J Clin Oncol.
2005;23:1136-43.
2. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken
EK, Deneffe GJ, et al. Prognostic importance of the standardized
uptake value on 18F-fluoro-2-deoxy-glucose-positron emission to-
mography scan in non-small-cell lung cancer: An analysis of 125
cases. J Clin Oncol. 1999;17:3201-6.
3. Sugawara Y, Quint LE, Iannettoni MD, Orringer MB, Russo JE,
Recker BE, et al. Does the FDG uptake of primary non-small cell lung
cancer predict prognosis?: A work in progress. Clin Positron Imaging.
1999;2:111-8.
4. Vesselle H, Turcotte E, Wiens L, Schmidt R, Takasagui JE, Lalani T, et
al. Relationship between non-small cell lung cancer fluorodeoxyglucose
uptake at positron emission tomography and surgical stage with relevance
to patient prognosis. Clin Cancer Res. 2004;10:4709-16.
5. Borst GR, Belderbos JSA, Boellaard R, Comans EFI, De Jaeger K,
Lammertsma AA, et al. Standardised FDG uptake: a prognostic factor
for inoperable non-small cell lung cancer. Eur J Cancer. 2005;
41:1533-41.
6. Pillot G, Siegel BA, Govindan R. Prognostic value of fluorodeoxy-
glucose positron emission tomography in non-small cell lung cancer.
A review. J Thorac Oncol. 2006;1:152-9.
7. Cerfolio RJ, Bryant AS, Ojha B, Eloubeidi M. Improving the inaccu-
racies of clinical staging of patients with NSLCC: a prospective trial.
Ann Thorac Surg. 2005;80:1207-13.
8. Roberts JR, Blum MG, Arildsen R, Drinkwater DC Jr, Christian KR,
Powers TA, et al. Prospective comparison of radiologic, thoracoscopic,
and pathologic staging in patients with early non-small cell lung
cancer. Ann Thorac Surg. 1999;68:1154-8.
e 2007
Discussion
Dr Carolyn R. Reed (Charleston, SC). When PET came on the
scene, all of us hoped that it would remarkably improve the
accuracy of clinical staging. Although PET, especially integrated
PET/CT, has increased staging accuracy, the multi-institutional
studies have somewhat dampened our initial enthusiasm. As we
have seen in other papers today, we must look at subsets of patients
to refine the utility of PET.
Recently, there has been a new focus on the intensity of FDG
uptake in an individual tumor as a surrogate marker of the biologic
behavior of that tumor. This is particularly attractive because
assessment of such things as cell proliferation markers and gene
expression profiling require tissue samples. Dr Downey’s paper
gives us insight into the true usefulness of PET and also, I believe,
its limitations.
Dr Downey, I think your study corroborates several known
things: the size cut-off point between T1 and T2 tumors should be
lower than 3 cm; small adenocarcinomas have better prognosis,
perhaps because histologies such as BAC and other GGOs are
included; and most importantly, postoperative pathologic stage is
still the key.
I do have one problem with the preoperative use of SUVMAX
because although at your institution an SUVMAX of less than 4.3
might be predictive of good prognosis, that might not be the case
at other institutions. SUV is a continuous variable, and a binary
cut-off point might not be appropriate. There are many factors, as
we all know, that affect the SUV determination. Therefore my first
question is this: How do we use your finding of an SUVMAX of 4.3
as a prognostic cut-off point? Should we establish our own insti-
tutional cut-off point?
Dr Downey. This is a problem that has been addressed before,
and it is a very important point. The standardized uptake value is
not standardized between institutions. It is just standardized within
an institution. Therefore a tumor measured to have an SUV of 4.3
in one institution might have a different measurement at another
institution. There is interest in the nuclear medicine field for trying
to come up with equipment similar to the phantom used in CT
scanning that would allow standardization of SUV measurements
between institutions, but thus far, there is no means of standard-
izing, and this just should be taken as a relative value.
The second question is about SUV being a continuous variable.
I believe that there are good reasons to consider treating SUV as a
binary variable. We have observed that patients who have an SUV
of less than 5 almost never have nodal metastases. In our earlier
article with 100 patients, there are 33 patients who had an SUV of
less than 5, and only one of them had a lymph node metastasis.
There are 67 patients with an SUV of greater than 5, and the
incidence of nodal metastases was 33%. We have made a similar
observation in patients with esophageal cancer that prognosis is
best defined by dichotomizing around an SUV of 5. Therefore
there might be a binary cut-off point, but this will require further
research.
Dr Reed. You say that 3 clinical variables are available pre-
operatively to give 3 prognostic categories, yet many of us do not
currently perform biopsies on small, highly PET-positive periph-
eral lesions before surgical intervention. You also used pathologic
T size and not a CT estimate. Do you now recommend biopsy of
all lesions to adequately prognosticate and perhaps, in addition,
supply tissue for other markers?
Dr Downey. Again, this is a very important point. To deter-
mine the prognostic value of PET SUV, what I did was to compare
PET with what would be the optimal combination of standard tests,
which would be if the fine-needle aspiration preoperatively told
you everything about the histology that the final pathology was
going to show you, and also radiographically they were able to
determine the same size that was determined by means of pathol-
ogy. Despite this being the best standard that could possibly be
obtained, PET still turned out to be an independent predictive
variable. Obviously, there is going to be degradation from that
high standard in common practice because if we try to measure
things radiographically, it will only approximate pathologically
measured size, and histology defined from a fine-needle aspiration
is never going to be as good as the final pathology. Therefore I
believe that the PET SUV might turn out to be the best indepen-
dent prognostic variable that we have available in the preoperative
period. I am not advocating needle biopsies in everyone.
Dr Reed. It was hoped that FDG-PET could be a useful tool in
identifying patients at high risk of recurrence with each stage,
particularly resected stage I and II disease. Because of your find-
ings, would you still favor a prospective multi-institutional study
looking at this issue in a homogeneous population of patients; that
is, those with surgically resected stage I and II disease?
Dr Downey. There are about 10 to 12 articles that have been
published looking at the prognostic significance of PET SUV.
Most recently there was Dr Cerfolio’s article from Alabama in
which he found results that were different from ours. He found that
the PET did predict survival independent of pathologic staging. It
was a smaller group of patients but still a very substantial number.
I have not talked to him to figure out why we have the results that
we have and he has results that he has. Therefore I would still
consider this an open question for development. I do not know
whether it requires a multi-institutional study.
Dr Reed. Finally, how would you use PET to stratify for
neoadjuvant therapy? Tell us what you would recommend for a
patient with clinical T2 N0 squamous cell carcinoma with an
SUVMAX of 10.
Dr Downey. We have a very low threshold for recommending
patients for neoadjuvant therapy; however, I think we might have
identified a group of patients who might not benefit. Although it is
somewhat of a philosophical question, it is not clear whether it
would be worth giving induction therapy to the group with the best
prognosis, who have a 3-year survival of 86%. We might be able
to reduce the number of patients who get referred for induction
therapy.
Dr Reed. I believe, finally, that this is a very important paper
because it refines the use of PET, and I want to congratulate Dr
Downey on a very nice presentation. Thank you very much.
Dr Downey. Thank you.
Dr Robert J. Cerfolio (Birmingham, Ala). Dr Miller said I can
only ask one quick question, and therefore I will try to ask you 2
quick questions.
First of all, I congratulate you on your findings, and I think our
findings are relatively similar, and we are corroborating one an-
other. There are some specifics. You grouped stage II and stage III
disease together. That might have been a factor, and we can talk
Downey et al General Thoracic Surgery
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about that later. But I think we do need a multi-institutional
prospective study, and I think we should look at neoadjuvant
therapy for the patients with stage IB disease. The patients with
stage IB disease are the ones we all know do poorly, and I think the
SUVMAX helps you identify the patients with stage IB disease who
do poorly. Therefore this is my chance to try to get all the world’s
experts who are here to participate in a study like that, which I
think we really need to do.
The second thing is that we need to get the SUVMAX to be the
same at different institutions. It is not that hard to do. The nuclear
radiologists tell us they can do it. Then an SUVMAX in Brazil will
be the same as an SUVMAX in New York or Birmingham.
Could you comment on the role of a prospective study looking
at neoadjuvant chemotherapy for a patient with stage IB disease
and how we would identify the patients with stage IB disease with
integrated PET/CT and not dedicated PET?
Dr Downey. I did not mention it, but in this group we transi-
tioned from just PET to PET/CT in the middle of this study at our
own institution. I think one of the most interesting findings was the
statistical phenomenon of an interaction that was seen in the
patients with clinical stage IB disease, such that if it is a discrimi-
nant, it is maybe most effective in telling you who is a good- and
a poor-risk patient with clinical stage IB disease. I am not sure that
I would use it to start off a multi-institutional trial involving
induction therapy at this point because there is no defined role for
induction therapy. I think that we need to simply validate that we
can identify preoperatively patients with something that correlates
with pathologic stage, and that would be best done across institu-
tions. What I think we have here is that it does show there is no
relationship between PET and pathology and therefore no addi-
tional benefit of adding PET to pathology; therefore we can use
pathologic stage as the gold standard, and it would be a relatively
straightforward study to do to define prognostic variables preop-
eratively, have surgeons assign a clinical stage, and then just find
out what they find at the operation a week later and see how close
we can get. Then after we have done that, shown what variables
work, then we can decide who should get induction therapy.
Dr Daniel L. Miller (Atlanta, Ga). Although I enjoyed your
presentation, I think the most important point about this is when
we look at visceral pleural invasion because we are getting to these
smaller tumors—2 cm, 1.5 cm—and they are peripheral, and they
are going to have a significant amount of visceral pleural invasion.
Your greatest crossover group was stage IA to IB disease, and I
think that probably was not measurement but was probably related
to visceral pleural invasion. We are looking back now to our own
data. There are actual lung cancers less than 3 cm with visceral
pleural invasion that are actually doing worse than those of 4 cm
without visceral pleural invasion. Did you look at visceral pleural
invasion at all?
Dr Downey. I do have a slide that showed that, but I did not
display it. The 2 areas, sort of the move from clinical to pathologic
stage, if we break it down by T, N, and M, it was not in the N and
the M category, it was in the T category, and it was not on
measured size. The majority of them, as you pointed out and you
picked up on, were going from T1 to T2 or T1 to T4. Less so, but
still those are the major areas that fell off.
Dr Miller. Well, I think it is more important now with our
pathologists with determining visceral pleural invasion at the time
of resection because they are all getting adjuvant treatment now for
stage IB disease, and if you are going to do a stage IB disease study
preoperatively, we are going to miss some patients because we are
not going to be able to identify that visceral pleural.
Dr Anthony P. Yim (Shatin, Hong Kong). Dr Downey, I really
enjoyed your paper.
Did you look at delayed SUV values apart from the SUVMAX,
and do they affect the outcome?
Dr Downey. No. Our nuclear medicine physicians have been
very interested, and I have been sort of peripheral to that work, in
trying to see whether there are any other parameters that work
better than the SUVMAX. They have tried integrating the SUV
across the tumor and various things, and they have never found
anything that they think is better in any of these data sets than the
SUVMAX of the primary site of disease.
Dr Yim. Just to comment, in my locality we still see a lot of
inflammatory disease, such as tuberculosis, and we pay a lot of
attention to the delayed value.
Dr Frank C. Detterbeck (New Haven, Conn). Rob, I have just
a comment. Maybe you know the answer to this better than I do,
but my understanding is that there are a lot of factors that go into
SUV, and I do not think it is as simple as just standardizing the
machine at one institution versus that at another. It has to do with
the activity of the FDG, the timing between the injection, and
when you scan. It also has to do with the size of the lesion. Once
the lesion is less than 2 cm, you have to correct for the size of the
lesion because otherwise you will underestimate it. It also has to do
with where in the lung the lesion is because if there is a lot of
movement, then you do the volume averaging on the PET scan just
like you do on the CT scan. Therefore there are a lot of factors. My
understanding is that determining a reproducible and reliable SUV
value is not at all straightforward or simple, but perhaps you know
more about this than I do or perhaps Rob Cerfolio does.
Dr Downey. I think actually Dr Cerfolio said it would be easier
to standardize between institutions. I do not think it will be
particularly that easy. It is the time between the injection versus
when it is scanned, the dose that is given. Your point about the
tumor size, though, I think is a very important one that has nothing
to do with the institution. The smaller the lesions are, the more
there is going to be a volume averaging. The CT scan is obtained
over the length of time that the PET scan lasts, and there will be
sort of a movement up and down, both smearing out the sort of
SUV value over a larger volume—relatively larger volume—but
also degrading the quality of the CT scan. Therefore these are all
things that have to be taken into account as we work on the
preoperative clinical variables.
Dr John Howington (Cincinnati, Ohio). Rob, nice presenta-
tion. There was discussion about needle biopsies and no-needle
biopsies, and then the discussion led over into doing induction
therapy for lesions with a high SUV. Being in Cincinnati, in the
histoplasma belt, I just cringe at the thought of a patient with a
solitary pulmonary nodule, with SUVs of 8, 9, and 10 that are
histoplasma, being mistakenly treated for cancer. The idea of
doing induction therapy in a patient without a tissue diagnosis is
hard for us to swallow.
Dr Downey. I was not advocating or arguing against fine-
needle aspirations. That was not the point of the paper.
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Dr Cerfolio. Well, since you invited me to answer that, Frank, I
would say that the formula that goes into the SUVMAX is not depen-
dent on where the nodule is located. It is not dependent on the size of
the nodule. It is a very specific formula that looks at the activity at a
pixel that can add some of those variables. Actually, those are prob-
ably less than 10% differences from talking to the GE guys who do
this every day. It has to do with the weight of the patient and the
injected dose, and those are very easily corroborated among centers
and organized. Therefore I do not think it is that hard to get an
SUVMAX to be the same across the world. I will shut up now.
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